Acupuncture in Chronic Migraine: A Randomized Controlled Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01096420|
Recruitment Status : Completed
First Posted : March 31, 2010
Last Update Posted : August 14, 2013
|Condition or disease||Intervention/treatment||Phase|
|Patients With Chronic Migraine||Procedure: acupuncture Drug: topiramate||Not Applicable|
Subjects who completed the prospective baseline periods and meet met the prespecified entry criteria will be randomized into 2 groups: acupuncture treatment, and topiramate treatment group.
Subjects will be allowed to continue taking acute migraine medications for the treatment of breakthrough attacks during the trial, but any migraine preventive medications will be prohibited.
Written informed consent was obtained from all participants before entering the study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||68 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Acupuncture in Chronic Migraine: A Randomized Controlled Trial|
|Study Start Date :||August 2008|
|Actual Primary Completion Date :||August 2010|
|Actual Study Completion Date :||August 2010|
Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.
Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).
Sterile disposable and steel needle (3210) were used .
The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi.
|Active Comparator: topiramate||
The patients were submitted to the topiramate treatment also for 12 consecutive weeks.
The study phase consists of a 4-week titration and a 8-week maintenance period.
All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).
Study drug was administered daily in equally divided twice daily doses.
- Mean monthly number of headache days with moderate or severe intensity [ Time Frame: 3 months ]a day with headache pain that lasts ≧ 4 h with peak severity of moderate or severe intensity, or any severity or duration if the subject takes and response to a triptan or ergot.
- ≥ 30% or ≥ 50% reduction in mean monthly headache days with moderate or severe intensity [ Time Frame: 3 months ]
- Mean monthly total headache days [ Time Frame: 3 months ]
- Reduction from baseline in the use of acute headache medications [ Time Frame: 3 months ]
- Short-Form 36-Item Health Survey(SF-36) [ Time Frame: 3 months ]
- Beck Depression Inventory(BDI) [ Time Frame: 3 months ]
- Migraine disability assessment questionnaire (MIDAS) [ Time Frame: 3 months ]
- Plasma CGRP level [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01096420
|Kuang Tien General Hospital|
|Taichung, Taiwan, 433|